
Focal Segmental Glomerulosclerosis- Pipeline Insight, 2024
Description
Focal Segmental Glomerulosclerosis- Pipeline Insight, 2024
DelveInsight’s, “Focal Segmental Glomerulosclerosis- Pipeline Insight, 2024” report provides comprehensive insights about 15+ companies and 18+ pipeline drugs in Focal Segmental Glomerulosclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Focal Segmental Glomerulosclerosis: Overview
Focal Segmental Glomerulosclerosis (FSGS) is a major cause of idiopathic steroid-resistant nephrotic syndrome (SRNS) and end-stage kidney disease (ESKD). The pathogenesis of focal segmental glomerular sclerosis involves a complex interplay of several cell types, including podocytes, endothelial cells, and the basement membrane. Podocytes are terminally differentiated cells that provide structural support to the glomerulus and are essential in maintaining an intact glomerular filtration barrier, which is essential to prevent nephrotic range proteinuria. Injury and loss of podocytes result in the podocyte hypertrophy of remaining podocytes to cover the glomerular capillary surface, resulting in effacement and protein loss. Foot process effacement and the proliferation of mesangial, endothelial, and epithelial cells earlier in the course of illness, followed by collapse or shrinkage of glomerular capillaries, all result in scarring (glomerulosclerosis).
The proposed mechanism for podocyte injury includes viral- or toxin-mediated insult and intrarenal hemodynamic alterations, such as high intraglomerular capillary pressure and glomerular hyperperfusion. Many morphologic subsets, such as a collapsing variant (FSGS with mesangial hypercellularity), a cellular variant (endocapillary and extracapillary hypercellularity), and FSGS with tip lesions, are known.
Understanding the pathophysiology of FSGS has improved with the discovery that mutations in several proteins responsible for maintaining podocyte structure, function, or both not only result in FSGS but can predict disease characteristics, such as steroid responsiveness. For instance, FSGS with mutations in NPHS2 or TRPC6 is challenging to treat with immunosuppressive therapy; however, when such patients undergo kidney transplantation, the disease does not usually recur. APOL1 G1/G2 variants have been associated with a poor renal prognosis and steroid resistance in nephrotic syndrome/FSGS.
""Focal Segmental Glomerulosclerosis- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Focal Segmental Glomerulosclerosis pipeline landscape is provided which includes the disease overview and Focal Segmental Glomerulosclerosis treatment guidelines. The assessment part of the report embraces, in depth Focal Segmental Glomerulosclerosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Focal Segmental Glomerulosclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Focal Segmental Glomerulosclerosis R&D. The therapies under development are focused on novel approaches to treat/improve Focal Segmental Glomerulosclerosis.
This segment of the Focal Segmental Glomerulosclerosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Focal Segmental Glomerulosclerosis Emerging Drugs
- DMX-200: Dimerix Bioscience
In 2020, DMX-200 demonstrated clear benefit to patients with FSGS in its first Phase IIa study in patients specifically with FSGS, following several successful studies in patients with a range of Chronic Kidney Diseases. All trial endpoints were achieved, and DMX-200 was determined to be safe and tolerable. DMX-200 is currently in a Phase III clinical trial for the treatment of FSGS.
- Sparsentan: Travere Therapeutics
- Dazodalibep: Horizon Therapeutics
Further product details are provided in the report……..
Focal Segmental Glomerulosclerosis: Therapeutic Assessment
This segment of the report provides insights about the different Focal Segmental Glomerulosclerosis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Focal Segmental Glomerulosclerosis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Intramuscular
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Product Type
Focal Segmental Glomerulosclerosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Focal Segmental Glomerulosclerosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Focal Segmental Glomerulosclerosis drugs.
Focal Segmental Glomerulosclerosis Report Insights
- Focal Segmental Glomerulosclerosis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Focal Segmental Glomerulosclerosis drugs?
- How many Focal Segmental Glomerulosclerosis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Focal Segmental Glomerulosclerosis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Focal Segmental Glomerulosclerosis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Focal Segmental Glomerulosclerosis and their status?
- What are the key designations that have been granted to the emerging drugs?
- Dimerix Bioscience
- Travere Therapeutics
- Horizon Therapeutics
- Pfizer
- Goldfinch Bio
- DMX-200
- Sparsentan
- Dazodalibep
- PF-06730512
- GFB-887
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Focal Segmental Glomerulosclerosis: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Focal Segmental Glomerulosclerosis– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- DMX-200: Dimerix Bioscience
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Dazodalibep: Horizon Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Focal Segmental Glomerulosclerosis Key Companies
- Focal Segmental Glomerulosclerosis Key Products
- Focal Segmental Glomerulosclerosis- Unmet Needs
- Focal Segmental Glomerulosclerosis- Market Drivers and Barriers
- Focal Segmental Glomerulosclerosis- Future Perspectives and Conclusion
- Focal Segmental Glomerulosclerosis Analyst Views
- Focal Segmental Glomerulosclerosis Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.